Sales & Marketing
Optimising HCP engagement through a data-driven omnichannel strategy
To encourage the uptake of complex therapies in clinical practice, …
19688 items found
News
CEPI-backed trial of Rift Valley fever jab starts in Kenya
A promising vaccine candidate for Rift Valley fever (RVF) has been …
News
GSK asthma hope depemokimab works in second indication
GSK's experimental IL-5 inhibitor depemokimab has shown its potential …
News
Baxter medicines in short supply after hurricane hits plant
Damage to a Baxter manufacturing facility caused by Hurricane Helene, …
Patients
Keeping stigma out of it: Personalising the mental health conversation
Thursday 10 th October was World Mental Health Day, focused this year …
News
FDA rethinking block on compounding of Lilly's obesity drug
The FDA has said it has agreed to reconsider its decision to prevent …
News
Pfizer rounds out haemophilia portfolio with FDA approval
Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA …
Market Access
Updating of England’s budget impact test threshold
England has a lot of ways to put downward pressure on prices of new …
R&D
Partner Content
BIO-Europe's 30th Anniversary Landmark Event in Stockholm
Through the everchanging landscape of life science partnering, …
News
Sanofi in talks to sell stake in consumer health spinout
Rumours that Sanofi was in discussion with private equity groups over …
Sales & Marketing
Changing Faces – Board appointments September 2024
September brought numerous noteworthy appointments to boards of …
News
Roche gets FDA green light for breast cancer drug Itovebi
The FDA has given Roche its first regulatory approval for PI3K …
News
NICE backs first targeted therapy for ALK+ lung cancer
Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.
Digital
Sponsored
Decoding physician prescribing behaviour: A data-driven jour...
Identifying high-volume prescribers and engaging with key opinion leaders (KOLs) in a target therapeutic area can be a challenge.
Sales & Marketing
Deep Dive: Commercialisation 2024
In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with its off-label use.
Digital
Sponsored
How to deal with fragmented data - A $12.9 million challenge
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
R&D
LSX 2024 - Dr Tadaaki Taniguchi
At LSX in Boston last month, editor-in-chief Jonah Comstock caught up with Dr Tadaaki Taniguchi, chief medical officer at Astellas Pharmaceuticals to talk a bit about the company and some r
Sales & Marketing
Sponsored
Launch Excellence: Moments of Truth
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
R&D
Partner Content
BIO-Europe's 30th Anniversary Landmark Event in Stockholm
BIO-Europe™ celebrates 30 years of facilitating partnerships this Fall. In 1994, BIO-Europe launched with the mission to drive biotech innovation and
R&D
Partner Content
8th Dermatology Drug Development Summit
Industry’s Destination to Discover & Develop Best-In-Class Drugs for Immuno-Inflammatory Skin Disease
